BDMD — Baird Medical Investment Holdings Income Statement
0.000.00%
Last trade - 00:00- $64.29m
- $83.12m
- $22.54m
Annual income statement for Baird Medical Investment Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 35.1 | 31.5 | 37 | 22.5 |
| Cost of Revenue | ||||
| Gross Profit | 28 | 27.2 | 32.7 | 18.9 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 21.5 | 19.6 | 21.7 | 48.2 |
| Operating Profit | 13.6 | 11.9 | 15.3 | -25.6 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 14.5 | 12.4 | 14.1 | -26.4 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 12.8 | 10.7 | 12.6 | -27.5 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | 12.6 | 10.5 | 12.5 | -27.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 12.6 | 10.5 | 12.5 | -27.3 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.484 | 0.406 | 0.571 | -0.981 |